Clinical trials recruiting in Vaasa, Finland

Phase breakdown

Conditions recruiting in Vaasa, Finland

Recruiting trials in Vaasa, Finland

• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
  NCT07099898 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer
  NCT07331519 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 74 Years · Sex: All (male and female)
• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
  NCT07252739 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
  NCT06328361 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease
  NCT06935786 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
  NCT06353386 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care
  NCT06005766 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male

Common questions

How many clinical trials are recruiting in Vaasa, Finland?

12 recruiting trials have at least one study site in Vaasa, Finland.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.